{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T01:40:29Z","timestamp":1730425229999,"version":"3.28.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,31]]},"DOI":"10.7759\/cureus.72796","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:58:36Z","timestamp":1730422716000},"source":"Crossref","is-referenced-by-count":0,"title":["Disseminated Tuberculosis in a Patient on Tumor Necrosis Factor (TNF)-\u03b1 Inhibitor Treatment for Ankylosing Spondylitis: A Case Report"],"prefix":"10.7759","author":[{"given":"Lana","family":"Fadl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arowa","family":"Abdelgadir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hibah","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aqsa","family":"Mahreen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddalingana Gouda","family":"Thaplar G Gouda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis. (2016). Accessed. October 31, 2024: https:\/\/www.nice.org.uk\/guidance\/ta383."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.746396","article-title":"Risk of adverse events after anti-TNF treatment for inflammatory rheumatological disease. A meta-analysis","volume":"12","author":"Li J","year":"2021","unstructured":"Li J, Zhang Z, Wu X, Zhou J, Meng D, Zhu P. Risk of adverse events after anti-TNF treatment for inflammatory rheumatological disease. A meta-analysis. Front Pharmacol. 2021, 12:746396. 10.3389\/fphar.2021.746396","journal-title":"Front Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2016.1202318","article-title":"A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study","volume":"46","author":"Chiu YM","year":"2017","unstructured":"Chiu YM, Tang CH, Hung ST, Yang YW, Fang CH, Lin HY. A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study. Scand J Rheumatol. 2017, 46:236-40. 10.1080\/03009742.2016.1202318","journal-title":"Scand J Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140102","article-title":"Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance","volume":"91","author":"Cantini F","year":"2014","unstructured":"Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl. 2014, 91:47-55. 10.3899\/jrheum.140102","journal-title":"J Rheumatol Suppl"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Zhang Z","year":"2017","unstructured":"Zhang Z, Fan W, Yang G, Xu Z, Wang J, Cheng Q, Yu M. Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017, 7:e012567. 10.1136\/bmjopen-2016-012567","journal-title":"BMJ Open"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei103","article-title":"British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments","volume":"44","author":"Ledingham J","year":"2005","unstructured":"Ledingham J, Wilkinson C, Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments. Rheumatology (Oxford). 2005, 44:1205-6. 10.1093\/rheumatology\/kei103","journal-title":"Rheumatology (Oxford)"},{"key":"ref7","unstructured":"Tuberculosis (TB). migrant health guide. (2023). Accessed: October 31, 2024: https:\/\/www.gov.uk\/guidance\/tuberculosis-tb-migrant-health-guide."},{"key":"ref8","unstructured":"TB incidence and epidemiology, England, 2022. (2024). Accessed. October 31, 2024: https:\/\/www.gov.uk\/government\/publications\/tuberculosis-in-england-2023-report-data-up-to-end-of-2022\/tb-incidence-an...."},{"key":"ref9","unstructured":"Tuberculosis. risk factors. (2023). Accessed: October 31, 2024: https:\/\/cks.nice.org.uk\/topics\/tuberculosis\/background-information\/risk-factors\/."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70089-X","article-title":"Mandell, Douglas, and Bennett's principles and practice of infectious diseases","volume":"10","author":"Zumla A","year":"2010","unstructured":"Zumla A. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Lancet Infect Dis. 2010, 10:303-4. 10.1016\/S1473-3099(10)70089-X","journal-title":"Lancet Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.22159\/ajpcr.2016.v9i5.12756","article-title":"A prospective study on abnormal LFT patterns in patients receiving antituberculosis therapy","volume":"9","author":"Vijayalakshmi A","year":"2016","unstructured":"Vijayalakshmi A, Thanmayi G, Jayakumari S. A prospective study on abnormal LFT patterns in patients receiving antituberculosis therapy. Asian J Pharm Clin Res. 2016, 9:136-9. 10.22159\/ajpcr.2016.v9i5.12756","journal-title":"Asian J Pharm Clin Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/312289-disseminated-tuberculosis-in-a-patient-on-tumor-necrosis-factor-tnf--inhibitor-treatment-for-ankylosing-spondylitis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:58:39Z","timestamp":1730422719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/312289-disseminated-tuberculosis-in-a-patient-on-tumor-necrosis-factor-tnf--inhibitor-treatment-for-ankylosing-spondylitis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.72796","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}